Heinz Hillen

USPTO Granted Patents = 30 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 163(Granted Patents)

Location History:

Ludwigshafen, DE (1988 - 1993)
Hassbloch, DE (2002)
Hassloch, DE (1994 - 2020)

Company Filing History:

15 out of 150

Abb Vie Deutschland Gmbh & Co. Kg

Basf Aktiengesellschaft

patents

4. 6 out of 4,177

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 1988-2020

Loading Chart...

30 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10538581 - Anti-Aβ globulomer 4D10 antibodies (2020-01-21),

2. 10464976 - Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2019-11-05),

3. 10323084 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-06-18),

4. 10208109 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-02-19),

5. 10047121 - Amyloid-beta binding proteins (2018-08-14),

6. 9951125 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2018-04-24),

7. 9822171 - Amyloid-beta binding proteins (2017-11-21),

8. 9540432 - Anti-Aβ globulomer 7C6 antibodies (2017-01-10),

9. 9394360 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2016-07-19),

10. 9359430 - Abeta conformer selective anti-Abeta globulomer monoclonal antibodies (2016-06-07),

11. 9176150 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2015-11-03),

12. 9062101 - Amyloid-beta binding proteins (2015-06-23),

13. 8987419 - Amyloid-beta binding proteins (2015-03-24),

14. 8895004 - Method for the treatment of amyloidoses (2014-11-25),

15. 8877190 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2014-11-04),

Title: Unveiling the Innovative Mind of Heinz Hillen

Introduction:

Heinz Hillen, a visionary inventor hailing from Hassloch, DE, is a prolific contributor to the field of medical innovations with an impressive portfolio of 30 patents under his name.

Latest Patents:

Among his recent groundbreaking patents is the development of Anti-Aβ globulomer 4D10 antibodies. These antibodies target Aβ globulomers associated with Alzheimer's disease, showcasing superior binding affinity compared to traditional antibodies, offering new avenues for therapeutic interventions in neurodegenerative disorders.

Additionally, Hillen's work on Amyloid β(1-42) oligomers and their derivatives has paved the way for innovative diagnostic and therapeutic agents. His method for reliable production of neuromodulatory oligomers has significant implications in the treatment and understanding of amyloidoses.

Career Highlights:

Having made significant contributions to the medical field, Heinz Hillen has left a mark during his tenure at AbbVie Deutschland GmbH & Co KG and AbbVie Inc. His relentless pursuit of innovation and commitment to advancing medical science have positioned him as a key figure in the industry.

Collaborations:

Throughout his career, Hillen has collaborated with esteemed professionals such as Andreas R Striebinger and Stefan Barghorn. These collaborations have not only enhanced the scope of his research but have also led to the development of impactful medical solutions.

Conclusion:

Heinz Hillen's unwavering dedication to innovation and his exceptional ability to translate cutting-edge research into practical applications underscore his significance in the realm of inventors. His patents stand as a testament to his ingenuity and relentless pursuit of advancements in medical science, leaving an indelible mark on the field of healthcare innovations.

This text is generated by artificial intelligence and may not be accurate.